ClinicalTrials.gg
RecruitingNCT07491497Updated Nov 5, 2026

A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC

A Phase 1/2 interventional study of TRI-611 in ALK-positive NSCLC, ALK-Positive Lung Cancer and ALK-positive Non-small Cell Lung Cancer, sponsored by TRIANA Biomedicines, Inc.. Recruiting at 20 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by TRIANA Biomedicines, Inc. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Nov 5, 2026First sites in France and United Kingdom4 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
160
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 3,371 studies in Carcinoma, Non-Small-Cell Lung with a site in United States — 521 open to participants now, 894 under way, 142 of them phase 3. Carcinoma, Non-Small-Cell Lung · United States.

Planned enrollment
752nd of 2,998
160 · median 56
Started
2026
with 130 others
Phase 1/2
486 of 3,371
119 open now
Primary completion
2029-05
later than 718 of 892 live
Registered
3,287th of 3,371
by date

Among the 3,371 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, this one is the 752nd largest by planned enrollment of the 2,998 interventional ones that give a count, is one of 131 that started in 2026, is one of 486 in phase 1/2, reaches primary completion later than 718 of the 892 other live ones, and was the 3,287th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

521 of the 3,371 studies in Carcinoma, Non-Small-Cell Lung with a site in United States are open now. Recruiting first, the newest first:

516 more — sign in →

All 521 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,371 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn about the safety and recommended dose of TRI-611 when administered to adults with ALK-positive non-small cell lung cancer (NSCLC). The trial will also evaluate the antitumor activity of TRI-611 in adults with ALK-positive NSCLC.

The study will be conducted in two parts. The first part will examine different doses of TRI-611. The second part will look at how well TRI-611 works on ALK-positive NSCLC when administered to three groups of participants that differ based on what type of prior therapy they have received.

In this study participants will:

  • Take TRI-611 on a continued basis, provided it is well-tolerated, for as long as their disease is not progressing
  • Visit the clinic approximately seven times in the first 3 months and then just once at the start of each 28-day cycle thereafter
  • Keep a diary of each time they take the study medication
Read the detailed description

This is a Phase 1/2 dose escalation and dose expansion study designed to evaluate the safety and tolerability of TRI-611, identify the maximum tolerated dose (MTD) and/or the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in participants with ALK-positive NSCLC.

Part 1 of the study consists of a dose escalation to determine the MTD and/or recommended dose(s) of TRI-611 for further exploration in two backfill cohorts.

Following completion of Part 1 of the study, Part 2 of the study will be initiated. The second part of the study is comprised of three cohorts (M1, M2, M3) of participants differentiated based on their previous treatment with ALK TKIs (tyrosine kinase inhibitors). During this part of the study the antitumor activity of TRI-611 will be further explored. See eligibility criteria for more details.

03

Conditions studied

  • ALK-positive NSCLC
  • ALK-Positive Lung Cancer
  • ALK-positive Non-small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed diagnosis of ALK-positive non-small cell lung cancer (NSCLC)
  • per v1.1
  • Adequate bone marrow reserve and organ function
  • Part 1: prior treatment with 2 to 3 ALK TKIs [in US only: '2 or more ALK TKIs'], prior treatment with lorlatinib is required but must not have been in the
  • Part 2 Cohort M1: prior treatment with 2 to 3 ALK TKIs, prior treatment with lorlatinib is required but must not have been in the first line, prior treatment with neladalkib is excluded
  • Part 2 Cohort M2: prior treatment with more than 3 ALK TKIs, prior treatment with lorlatinib and neladalkib is required but neither may have been in the first line
  • Part 2 Cohort M3: participants without prior ALK TKI treatment

Exclusion criteria

Exclusion Criteria:

  • Participant's cancer has any additional driver alterations known to be a mechanism of resistance to ALK TKIs
  • For participants with central nervous system (CNS) or spinal cord compression, they must not be associated with progressive neurological symptoms or require increasing doses of to control the CNS disease
  • Ongoing treatment with another anticancer treatment or agent
  • Known allergy/ to TRI-611 or any of its ingredients
  • Major surgery within 4 weeks of receiving the first dose of TRI-611
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    Part 1: Dose Escalation and Backfill

    Prior treatment with 2 to 3 ALK TKIs, prior treatment with lorlatinib is required but must not have been in the first line

    Drug: TRI-611

  • Experimental
    Part 2: Cohort M1

    Prior treatment with ALK TKIs, including lorlatinib. Prior treatment with neladalkib is excluded

    Drug: TRI-611

  • Experimental
    Part 2: Cohort M2

    Prior treatment with ALK TKIs, including lorlatinib. Prior treatment with neladalkib is required

    Drug: TRI-611

  • Experimental
    Part 2: Cohort M3

    Participants without prior ALK TKI treatment

    Drug: TRI-611

Interventions

  • DrugTRI-611

    oral ALK molecular glue degrader

06

What researchers measure

Primary outcomes

  1. Part 1: Treatment emergent adverse events

    Treatment emergent adverse events (TEAEs)

    Time frame: Within 28 days of the first TRI-611 dose

  2. Part 2: Objective response rate (ORR)

    Determine the objective response rate (ORR) based on RECIST v1.1

    Time frame: Approximately 16 weeks after the last participant dosed in Part 2

  3. Part 2: Depth of response (DofR)

    Defined as the greatest percentage reduction in the sum of diameters of target lesions from baseline

    Time frame: Approximately 16 weeks after the last participant dosed in Part 2

Secondary outcomes

  1. Part 1: Half-life (t1/2) of TRI-611

    Determine the t1/2 of TRI-611

    Time frame: Pre-dose and up to 24 hours post-dose

  2. Part 1: Area under the curve (AUC) of TRI-611

    Determine the AUC of TRI-611

    Time frame: Pre-dose and up to 24 hours post-dose

  3. Part 1: Maximum plasma concentration (Cmax) of TRI-611

    Determine the Cmax of TRI-611

    Time frame: Pre-dose and up to 24 hours post-dose

  4. Part 1: Minimum plasma concentration (Cmin) of TRI-611

    Determine the Cmin of TRI-611

    Time frame: Pre-dose and up to 24 hours post-dose

  5. Part 1: ORR

    Determine the ORR based on RECIST v1.1

    Time frame: Approximately 16 weeks after the last participant dosed in Part 1

  6. Part 1: DofR

    Defined as the greatest percentage reduction in the sum of diameters of target lesions from baseline

    Time frame: Approximately 16 weeks after the last participant dosed in Part 1

  7. Parts 1&2: Duration of response (DOR)

    Determine the DOR based on RECIST v1.1

    Time frame: Approximately 5 years after the last participant is dosed with TRI-611

  8. Parts 1&2: Disease control rate (DCR)

    Defined as the number and percentage of participants who have achieved a response or stable disease based on RECIST v1.1

    Time frame: Approximately 16 weeks after the last participant dosed

  9. Parts 1&2: Clinical Benefit Rate (CBR)

    Defined as the number and percentage of participants who have achieved a response or stable disease based on RECIST v1.1 maintained for a minimum of 6 months

    Time frame: Approximately 9 months after the last participant is dosed

  10. Parts 1&2: Progression-free survival (PFS)

    Determine PFS based on RECIST v1.1

    Time frame: Approximately 5 years after the last participant is dosed with TRI-611

  11. Parts 1&2: Overall survival (OS)

    Determine OS based on RECIST v1.1

    Time frame: Approximately 5 years after the last participant is dosed with TRI-611

  12. Parts 1&2: Central Nervous System (CNS) objective response rate (ORR)

    Determine CNS ORR based on modified RECIST (mRECIST v1.1) in participants with CNS metastasis at baseline

    Time frame: Approximately 16 weeks after the last participant dosed

  13. Parts 1&2: CNS duration of response (DOR)

    Determine CNS DOR based on mRECIST v1.1 in participants with CNS metastasis at baseline

    Time frame: Approximately 5 years after the last participant is dosed with TRI-611

  14. Parts 1&2: Time to intracranial progression (TTP)

    Defined as the time to the date of the first documentation of objective progression of intracranial disease

    Time frame: Approximately 5 years after the last participant is dosed with TRI-611

  15. Part 1: Profile changes in tumor ALK-fusion protein levels

    Assessing treatment-induced modulation of ALK expression only in participants consenting to on-treatment biopsies

    Time frame: Approximately 14 days after the last dose of participants in Part 1 that have consented to on-treatment biopsies

07

Study locations

20 of 20 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for May 2029, 38 months after the start.

Of 309 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's planned 38 months is below that.

Counting every sponsor, half of 432 studies reached it within 63 months; a quarter within 42 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2026
First posted
Mar 24, 2026
StartActual
Mar 11, 2026
Primary completionEst.
May 31, 2029
CompletionEst.
Jan 30, 2034
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added — first sites in France and United Kingdom
Show 4 added (2 France, 1 Australia, 1 United Kingdom)
  • Westmead Hospital · Westmead, Australia
  • Centre Léon Bérard · Lyon, France
  • Gustave Roussy Institute · Villejuif, France
  • The Royal Marsden NHS Foundation · Sutton, United Kingdom
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    4 sites added — first sites in France and United Kingdom
    Show 4 added (2 France, 1 Australia, 1 United Kingdom)
    • Westmead Hospital · Westmead, Australia
    • Centre Léon Bérard · Lyon, France
    • Gustave Roussy Institute · Villejuif, France
    • The Royal Marsden NHS Foundation · Sutton, United Kingdom
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07491497
Lead sponsor
TRIANA Biomedicines, Inc.
Responsible party
Sponsor
First posted
Mar 24, 2026
Start date
Mar 11, 2026
Primary completion
May 31, 2029 (estimated)
Completion
Jan 30, 2034 (estimated)
Last update
Nov 5, 2026

Study contacts

TRIANA Clinical Trials
Contact
medical@trianabio.com

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion